The Office of the U.S. Trade Representative on Thursday launched an investigation against Germany under Section 301 of the Trade Act of 1974 to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts U.S. commerce.
19 Jun 2026-07:22
